spacer
home > ebr > summer 2002 > why r&d matters
PUBLICATIONS
European Biopharmaceutical Review

Why R&D Matters

In his most recent Budget, the Chancellor announced the R&D tax credit for larger companies, complementing the R&D tax credit for small and medium-sized companies introduced in Budget 2000. Together the two credits will represent £500 million a year in additional Government support for business R&D investment in the UK. This level of commitment reflects the Government's determination to increase the level of R&D investment by UK industry. As Figure 1 shows, business R&D intensity in the UK does not fare well with comparable economies.Figure 1 shows the overall average business R&D intensity in the UK, but the picture varies from sector to sector. At 14.8 per cent of sales (1), R&D investment by the UK pharmaceutical industry is competitive by international standards - although recent years have seen a trend for UK-owned groups to undertake an increasing proportion of their R&D outside the UK, and we estimate a decline in the UK share of worldwide pharmaceutical R&D from 11 per cent to 9 per cent (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dawn Primarolo MP, Paymaster General for HM Treasury

Dawn Primarolo MP was appointed Paymaster General on 4th January 1999. She has overall responsibility for Inland Revenue and Customs and Excise duties and taxes, and for HM Treasury.
Member of Parliament for Bristol South since 1987, Dawn was educated at Thomas Bennet Comprehensive in Crawley, Bristol Poly and Bristol University. Before entering Parliament, she was member of Avon County Council from 1985 to 1987.
In Opposition, Ms Primarolo was Front Bench Spokesperson on health from 1992 to 1994, and Treasury affairs between 1994 and 1997. She was appointed Financial Secretary to the Treasury on 4th May 1997.

spacer
Dawn Primarolo MP
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite

Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement